Cargando…

Inclisiran: a novel drug for the treatment of dyslipidemia

Detalles Bibliográficos
Autores principales:	Nadeem, Abdullah, Tariq, Rabeea, Basaria, Areeba
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893436/ https://www.ncbi.nlm.nih.gov/pubmed/36742122 http://dx.doi.org/10.1097/MS9.0000000000000089

Ejemplares similares

Infectious diseases following hydrometeorological disasters: current scenario, prevention, and control measures
por: Basaria, Areeba A.A., et al.
Publicado: (2023)

Novel Therapeutic Strategies for Dyslipidemia: First Report of Inclisiran Therapy in a Kidney Transplanted Patient
por: Ueberdiek, Lars, et al.
Publicado: (2023)

Corrigendum: Novel Therapeutic Strategies for Dyslipidemia: First Report of Inclisiran Therapy in a Kidney Transplanted Patient
por: Ueberdiek, Lars, et al.
Publicado: (2023)

Inclisiran: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Correction to: Inclisiran: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Effectiveness and safety of Inclisiran in hyperlipidemia treatment: An overview of systematic reviews
por: Li, Jiayi, et al.
Publicado: (2023)

New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran
por: Ruscica, Massimiliano, et al.
Publicado: (2021)

Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis
por: Rogula, Sylwester, et al.
Publicado: (2021)

Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia
por: Ebenezer, Oluwakemi, et al.
Publicado: (2023)

Guidelines on the Clinical Evaluation of Medicinal Products for Treatment of Dyslipidemia
por: Yamashita, Shizuya, et al.
Publicado: (2020)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023)

Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia
por: Kosmas, Constantine E., et al.
Publicado: (2018)

Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials
por: Cupido, Arjen J, et al.
Publicado: (2020)

Inclisiran: How Widely and When Should We Use It?
por: Pirillo, Angela, et al.
Publicado: (2022)

A rare case of mandibular third molar displaced into submandibular space: A complication of mandibular third molar extraction
por: Nadeem, Abdullah, et al.
Publicado: (2023)

Inclisiran—A Revolutionary Addition to a Cholesterol-Lowering Therapy
por: Dec, Adrianna, et al.
Publicado: (2023)

Inclisiran adjuvant therapy to statins for the use of hypercholesterolemia: a commentary
por: Vohra, Laiba Imran, et al.
Publicado: (2023)

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
por: Ray, Kausik K, et al.
Publicado: (2022)

Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
por: Kosmas, Constantine E, et al.
Publicado: (2020)

Inclisiran: a new generation of lipid-lowering siRNA therapeutic
por: Zhang, Yanzhen, et al.
Publicado: (2023)

Lipid lowering with inclisiran: a real-world single-centre experience
por: Padam, Pritpal, et al.
Publicado: (2022)

Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
por: Wołowiec, Łukasz, et al.
Publicado: (2023)

Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus
por: Rakocevic, Jelena, et al.
Publicado: (2023)

The Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) Perspectives on the Usage of Inclisiran
por: Elserafy, Ahmed Shawky, et al.
Publicado: (2022)

Consensus statement on the management of dyslipidemia in Indian subjects: Our perspective
por: Bansal, Manish, et al.
Publicado: (2016)

Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
por: Nishikido, Toshiyuki
Publicado: (2023)

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
por: Ray, Kausik K, et al.
Publicado: (2022)

Can Clinicians Start Prescribing Inclisiran for Hypercholesterolemia Today? A Review of Clinical Studies for Internal Medicine Physicians and Endocrinologists
por: Jahangir, Abdullah, et al.
Publicado: (2021)

Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease
por: Albosta, Michael S, et al.
Publicado: (2023)

The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function
por: Di Costanzo, Assunta, et al.
Publicado: (2023)

PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis
por: Kong, Ni, et al.
Publicado: (2022)

Metabolic Syndrome and Dyslipidemia among Nigerians with Lichen Planus: A Cross-Sectional Study - Reader's Question
por: Al-Mendalawi, Mahmood D.
Publicado: (2020)

Author's Reply- Metabolic Syndrome and Dyslipidemia Among Nigerians with Lichen Planus: A Cross-sectional Study
por: Okpala, Ifeanyi Chibuzor, et al.
Publicado: (2020)

Screening and management of dyslipidemia in oncologic patients undergoing cardiotoxic therapies: results from an Italian survey
por: Camilli, Massimiliano, et al.
Publicado: (2023)

Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11
por: Koenig, Wolfgang, et al.
Publicado: (2023)

Serum fibroblast growth factor 19 (FGF19) levels are associated with atherogenic dyslipidemia in patients with type 2 diabetes
por: Hu, Jing-Yi, et al.
Publicado: (2021)

Type 2 diabetes drug glitazone may help lowering risk of dementia by 22%
por: Fareed, Areeba, et al.
Publicado: (2023)

An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study
por: Kallend, David, et al.
Publicado: (2022)

“Indus Kay Sitaray”: A novel hospital-based school at The Indus Hospital, Karachi
por: Akhtar, Tooba Nadeem, et al.
Publicado: (2020)

Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review
por: Merćep, Iveta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0qo6hac8iusu8m3usj5rpgc04c